Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
FDA approves immunotherapy plus targeted therapy combo for initial treatment of advanced renal cell carcinoma.
Ed Doelp lives with his wife, Dawn, in Smithville, New Jersey. Now in his 60s, he was diagnosed with kidney cancer in 2012.
Immunotherapy and targeted therapy combo is now approved for first-time treatment of advanced renal cell carcinoma.
In two large clinical trials, an immune checkpoint inhibitor combined with a targeted therapy had better outcomes than the standard of care.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
First-line immunotherapy combo delayed disease progression and reduced the risk of death by nearly half.
Bavencio or Keytruda plus targeted therapy slowed disease progression in Phase III studies.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.